Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial health with improved net loss, a solid cash position, and manageable debt. The European market expansion and patent extension efforts indicate growth potential. The Q&A session reveals optimism about new patient growth and strategic collaborations, despite some uncertainties. The positive sentiment is bolstered by successful disease awareness campaigns and partnerships. However, variability in sales and lack of specific guidance on some metrics may temper immediate expectations. Overall, the sentiment leans positive, suggesting a likely stock price increase within the 2% to 8% range.
Key Financial Performance
Net Revenue (Full Year 2025) $106.5 million, driven by the performance of MIPLYFFA, which delivered $87.4 million in revenue. This reflects strong commercial performance and increasing adoption of MIPLYFFA.
Net Revenue (Q4 2025) $34.1 million, including $26.4 million from MIPLYFFA sales. This growth was driven by increased adoption among previously diagnosed and newly diagnosed patients.
Operating Expenses (Q4 2025) $23 million, a decrease of $1.5 million year-over-year, primarily due to a reduction in R&D expenses.
R&D Expense (Q4 2025) $2.6 million, a decrease of $5.8 million year-over-year, primarily due to a decrease in personnel-related and third-party costs.
SG&A Expense (Q4 2025) $20.4 million, an increase of $4.3 million year-over-year, largely due to investments to support launch activities.
Net Income (Q4 2025) $12.2 million or $0.20 per basic share, compared to a net loss of $35.7 million or $0.67 per share in Q4 2024. This improvement reflects strong revenue growth and controlled expenses.
Operating Expenses (Full Year 2025) $90.4 million, a decrease of $6.6 million year-over-year, driven by reduced R&D expenses.
R&D Expense (Full Year 2025) $12.7 million, a decrease of $29.4 million year-over-year, primarily due to a decrease in personnel-related and third-party costs.
SG&A Expense (Full Year 2025) $77.6 million, an increase of $22.7 million year-over-year, mainly due to increased costs related to MIPLYFFA and launch activities.
Net Income (Full Year 2025) $83.2 million or $1.40 per basic share, compared to a net loss of $105.5 million or $2.28 per share in 2024. This improvement reflects strong revenue growth and controlled expenses.
Cash, Cash Equivalents, and Investments (End of 2025) $238.9 million, providing a strong financial position.
Total Debt (End of 2025) $61.9 million, indicating a manageable debt level.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MIPLYFFA Revenue: Generated $87.4 million in revenue in 2025, with $26.4 million in Q4 alone. It is the foundational treatment for Niemann-Pick Disease Type C (NPC).
Celiprolol Development: Advanced Phase III DISCOVER study for Vascular Ehlers-Danlos Syndrome (VEDS), enrolling 52 patients by year-end 2025.
Global Expansion of MIPLYFFA: Expanded access through a global expanded access program (EAP) with 113 patients enrolled by the end of 2025. Established a new distribution agreement to extend EAP to territories outside Europe.
European Market for MIPLYFFA: Submitted marketing authorization application to the European Medicines Agency. Supporting nearly 10% of the estimated 1,100 NPC patients in Europe through EAP.
Headquarters Relocation: Moved headquarters to Boston to enhance collaboration and access to specialized talent.
AI-Driven Patient Identification: Developed an AI predictive model to identify undiagnosed NPC patients using claims data and electronic health records.
Patent Term Extension for MIPLYFFA: Pursuing a patent term extension in the U.S. to extend exclusivity beyond 2031.
FDA Engagement for Celiprolol: Engaged the FDA in discussions to accelerate the development program for Celiprolol.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company is facing regulatory challenges in Europe, as evidenced by the 120-day list of questions received from EU regulators regarding the marketing authorization application for arimoclomol. This could delay approval and market entry.
Supply Chain Variability: The global expanded access program (EAP) for MIPLYFFA is subject to variability in ordering patterns and the rate of new enrollments, which could impact revenue stability in the early years.
Enrollment Challenges: The Phase III DISCOVER study for Celiprolol has enrolled only 52 of the planned 150 patients, indicating slow enrollment progress. This could delay the study's completion and subsequent regulatory approval.
Market Access and Reimbursement: While 68% of total covered lives have been achieved for MIPLYFFA, securing reimbursement for the remaining patients remains a challenge, potentially limiting market penetration.
Geographic Expansion Risks: Efforts to expand MIPLYFFA's reach in Europe and other territories depend on strategic partnerships and regulatory approvals, which carry inherent risks of delays or failures.
Operational Costs: Increased SG&A expenses, primarily due to investments in launch activities and personnel, could strain financial resources if revenue growth does not keep pace.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company anticipates multiple growth drivers in 2026, building on the momentum of 2025's net revenue of $106.5 million, primarily driven by MIPLYFFA sales.
MIPLYFFA Exclusivity: MIPLYFFA has exclusivity in the U.S. through 2031 under the Orphan Drug Designation. The company is pursuing a patent term extension, which, if granted, would extend exclusivity further.
European Market Expansion: The company has submitted a marketing authorization application to the European Medicines Agency for MIPLYFFA and is prepared to respond to regulatory questions. The European NPC prevalence is estimated at 1,100 individuals, and the company aims to maximize commercial impact through strategic partnerships or independent operations.
Celiprolol Development: The ongoing Phase III DISCOVER study for Celiprolol aims to confirm clinical benefits for Vascular Ehlers-Danlos Syndrome (VEDS). The company is engaging with the FDA to explore regulatory options to accelerate the development program, with further engagement expected in the second half of the year.
Global Expanded Access Program (EAP): The company is expanding access to MIPLYFFA globally, with 113 patients enrolled in the EAP by the end of 2025. A new distribution agreement extends the EAP to territories outside Europe, though variability in ordering patterns is anticipated initially.
AI-Driven Patient Identification: The company is leveraging an AI predictive model to identify undiagnosed NPC patients, which is expected to drive new patient identification and market growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the split of new diagnoses versus identified patients on drug for the '24 start forms?
A:Management highlighted variability in quarter-over-quarter data but emphasized confidence in the U.S. prevalence. They noted meaningful growth in newly diagnosed patients, attributed to clinical data, real-world experience, and disease awareness campaigns. Collaborations with genetic testing companies were also expanded.
Q:What is the average time from initial suspicion to confirmed diagnosis?
A:Management stated it is difficult to provide an average time due to variability in rare disease symptoms. They emphasized efforts in physician education and AI models to improve diagnosis. GeneDx collaboration estimates results within 3 weeks from testing.
Q:What is the next step in the EMA submission process?
A:Management confirmed submission within the 90-day clock stop period and clarified the next step is the 150-day questions, not 180.
Q:Can you provide an estimate of the proportion of patients staying on therapy long-term?
A:Management stated it is too early to provide meaningful data on persistency but expressed encouragement from refill rates and durability of response observed in clinical and real-world data.
Q:What is the initial experience with the Uniphar collaboration, and how does it contribute to growth?
A:Management expressed satisfaction with Uniphar's performance, noting quick product delivery to patients. They expect variability in ordering patterns but anticipate continued growth and broader access outside Europe.
Q:Do you have an updated sense of the total addressable number of patients in the U.S.?
A:Management reiterated confidence in the addressable market being between 300-350 diagnosed patients and 900 prevalent cases. They noted increasing confidence due to efforts in genetic testing and disease awareness.
Q:Does the EAP revenue represent a new recurring quarterly run rate?
A:Management clarified that EAP revenue is based on named patient basis reimbursed sales and will show variability. French EAP program remains steady at approximately 30 patients, generating $10 million annually, with additional revenue from new territories.
Q:How is the gross-to-net evolving in the U.S.?
A:Management noted gross-to-net has evolved due to the Inflation Reduction Act but did not provide specific guidance, citing dynamic factors.
Q:Do you expect continued sequential growth in U.S. sales of MIPLYFFA?
A:Management expects variability in sales due to the ultra-rare nature of the disease and the small patient base but remains confident in the addressable market.
Q:What is the average age of patients on MIPLYFFA, and how prepared is the company for competition?
A:Management stated the patient mix is approximately 50% adults and 50% children. They welcome competition and believe MIPLYFFA is viewed as a foundational treatment by clinicians.
Q:Has the EMA asked for any new clinical data for arimoclomol's pending applications?
A:Management stated no new clinical data has been requested and emphasized the robustness of their submitted data package.
Q:What steps are being taken to accelerate the Celiprolol program?
A:Management highlighted efforts to boost enrollment and engage the FDA in discussions to explore regulatory options, aiming to expedite patient access.
Q:How should we think about annual enrollment numbers going forward?
A:Management emphasized confidence in the long runway for growth, driven by efforts in diagnosing new patients and addressing barriers. They did not provide specific guidance for 2026.
Q:What portion of diagnosed NPC patients in the U.S. has the company engaged through its programs?
A:Management estimated that 40-50% of diagnosed patients are currently enrolled to receive MIPLYFFA.
Q:What contributed to the increase in new patient starts in Q4?
A:Management attributed the increase to a combination of factors, including disease awareness campaigns, AI-driven targeting models, and enhanced commercial execution.
Q:How is the company approaching capital allocation given its strong balance sheet?
A:Management emphasized a focus on executing current opportunities, including U.S. market expansion, geographic expansion, and pipeline investment. They evaluate capital allocation quarterly.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on gross-to-net evolution, persistency rates, and future annual enrollment numbers, citing dynamic factors and early stages of the launch.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Celiprolol
Corporate
EAP royalty
EU
Europe
GeneDx
III
MIPLYFFA sale
Type
VEDS
access diagnosis
afternoon
agency
analysis
arimoclomol
benefit
community
day
diagnosis disease
disease awareness
engagement
enrollment form
event
expense decrease
identification
individual
people
personnel
plan
reimbursement
reminder
review
safety
section
therapy patient
treatment NPC
ZVRA Transcript
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary lacks substantial information on financial performance, strategic initiatives, and shareholder returns. The absence of these details, combined with the acknowledgment of risks in forward-looking statements, suggests a neutral sentiment. Without explicit positive or negative financial metrics, guidance, or new strategic announcements, the stock price is unlikely to experience significant movement in the short term.
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call highlights strong financial health with improved net loss, a solid cash position, and manageable debt. The European market expansion and patent extension efforts indicate growth potential. The Q&A session reveals optimism about new patient growth and strategic collaborations, despite some uncertainties. The positive sentiment is bolstered by successful disease awareness campaigns and partnerships. However, variability in sales and lack of specific guidance on some metrics may temper immediate expectations. Overall, the sentiment leans positive, suggesting a likely stock price increase within the 2% to 8% range.
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
IAMGOLD Corporation (IMG:CA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reveals strong financial performance with record high revenue and adjusted EBITDA, which are positive indicators. The Q&A section provides clarity on cost improvements and share buybacks, boosting investor confidence. Although some responses lacked specificity, the overall sentiment is positive due to strategic capital allocation and growth plans. The company's robust financial health and clear strategies for cost reduction and production expansion further support a positive outlook.
ZVRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
